Supply chain leaders argue that visibility alone is insufficient without decision-centric data utilization. This highlights Dassault Systèmes' thought leadership in enterprise data strategy.
Dassault Systèmes has launched three new virtual companions, Aura, Leo, and Marie, on its 3DExperience platform. This release enhances user interaction and AI-driven capabilities within their engineering software ecosystem.
Seeking Alpha published a financial analysis highlighting the return of industrial growth alongside ongoing weakness in the life sciences segment. This performance divergence provides investors with key insights into the company's valuation and segment-level recovery.
Medidata, a Dassault Systèmes brand, launched Medidata Plus to standardize clinical trial data and workflows using embedded AI. This release helps life sciences companies overcome fragmented point solutions and bridge the gap between AI spending and expectations.
Nordic Capital has agreed to sell life sciences software provider ArisGlobal to Dassault Systèmes. This strategic acquisition expands Dassault Systèmes' software portfolio and market reach in the life sciences sector.
Dassault Systèmes has made its 2026 half-year financial report publicly available for investors and stakeholders. This transparency ensures market compliance and provides insight into the company's mid-year financial health.
Dassault Systèmes released its 2026 second-quarter earnings presentation for investors and stakeholders. The report provides key financial metrics and performance updates crucial for evaluating the company's business health.
Dassault Systèmes confirmed its 2026 financial outlook and announced a $1.8 billion acquisition of ArisGlobal to boost its AI capabilities. This major strategic move expands the company's life sciences and AI-driven portfolio.
Dassault Systèmes reported strong Q2 financial results and confirmed its full-year guidance. This demonstrates steady financial health and continued momentum in AI-native solutions.
Dassault Systèmes announced the acquisition of ArisGlobal to create a unified AI intelligence platform for the life sciences sector. This strategic move strengthens the company's software offerings in healthcare and life sciences.
Dassault Systèmes reported its second-quarter 2026 results, confirming its full-year outlook and announcing a definitive agreement to acquire U.S.-based life sciences platform ArisGlobal for $1.8 billion. The acquisition aims to expand its AI-native capabilities in healthcare, while its core manufacturing and 3D software divisions showed steady cloud growth.
In its second-quarter earnings presentation, Dassault Systèmes highlighted solid financial results and a major strategic pivot into an AI-native agentic platform. The company emphasized how its 3D design and simulation tools are evolving to incorporate automated virtual companions for industrial and scientific applications.
Dassault Systèmes confirmed its full-year financial outlook following in-line second-quarter results and announced a major $1.8 billion acquisition of U.S.-based software maker ArisGlobal to expand its life sciences footprint.
Dassault Systèmes is increasingly positioning its software platforms to bridge the gap between manufacturing and construction in the AEC industry. This strategic bet aims to transform traditional building information modeling into advanced manufacturing-style workflows.
At its recent AEC Summit, Dassault Systèmes outlined its strategy to reposition its core modeling tools like Catia toward construction-specific fabrication, treating the AEC industry more like a manufacturing process.
Dassault Systèmes is reportedly in negotiations to acquire ArisGlobal, a drug trial software provider, for approximately $2 billion. This acquisition would significantly strengthen the company's position and capabilities within the life sciences technology sector.
Dassault Systèmes is reportedly in negotiations to acquire the drug trial software firm ArisGlobal for approximately $2 billion. This move signals a significant expansion of the company's life sciences and healthcare technology portfolio.
Headlines surfaced and scored by PortcoMonitor. Get the full, ranked feed + a daily briefing →